Articles published by SOLVE FSHD

SOLVE FSHD Accelerates Development of SFH-4090, a Novel DUX4 Inhibitor for FSHD

Today 17:00 EDT

From SOLVE FSHD

Via Business Wire

SOLVE FSHD Announces Recent Grant Awards to Accelerate Treatments for Facioscapulohumeral Muscular Dystrophy

April 27, 2026

From SOLVE FSHD

Via Business Wire

SOLVE FSHD and Modalis Announce Strategic Collaboration to Develop an Innovative CRISPR-Based Epigenome Editing Treatment for Facioscapulohumeral Muscular Dystrophy

June 08, 2025

From SOLVE FSHD

Via Business Wire

SOLVE FSHD Announces $3 Million Investment in Armatus Bio to Advance Gene Therapy Program for FSHD

May 06, 2025

From SOLVE FSHD

Via Business Wire

SOLVE FSHD Announces Strategic Collaboration with Transcripta Bio to Advance Drug Discovery for FSHD

March 25, 2025

From SOLVE FSHD

Via Business Wire

SOLVE FSHD Challenges Innovators with USD$10 Million Bonus Prize to Accelerate FSHD Breakthroughs in XPRIZE Healthspan Competition

December 05, 2024

From SOLVE FSHD

Via Business Wire

SOLVE FSHD Announces New Collaborative Research Grants to Accelerate Novel Potential Therapeutics for Facioscapulohumeral Muscular Dystrophy (FSHD)

July 11, 2023

From Solve FSHD

Via GlobeNewswire

SOLVE FSHD invests in Epic Bio for the development of a novel treatment for Facioscapulohumeral Muscular Dystrophy

April 18, 2023

From Solve FSHD

Via GlobeNewswire

CORRECTION -- SOLVE FSHD invests US$10 Million in Vita Therapeutics

October 13, 2022

From Solve FSHD

Via GlobeNewswire

SOLVE FSHD invests US$10 Million in Vita Therapeutics

October 13, 2022

From Solve FSHD

Via GlobeNewswire

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.